Podcasts about frontline

Frontline hiring has always been fast-paced, but lately it feels like we're in the middle of a complete reset. Candidates are choosing jobs differently, expectations are shifting, and the old playbooks really aren't holding up anymore. Even with better tools, more data, and smarter strategies, companies are still struggling to attract and keep frontline talent. So clearly, something deeper is going on beneath the surface.  And to break this down with us, I'm joined by someone who's been watching these changes unfold in real time, Trent Cotton, Head of Talent Acquisition Insights & Analyst Relations at iCIMS. 

Frontline uniformed gardaí could be using Taser stun guns almost immediately under a proposal being brought to Government by Minister for Justice Jim O'Callaghan. The stun guns could be used in policing on the streets of Dublin, Waterford and Kilkenny over the Christmas period, if approved by Cabinet today.

Frontline uniformed gardaí could be using Taser stun guns almost immediately under a proposal being brought to Government by Minister for Justice Jim O'Callaghan. The stun guns could be used in policing on the streets of Dublin, Waterford and Kilkenny over the Christmas period, if approved by Cabinet today.

In this week's MBA Admissions podcast we began by discussing the current state of the MBA admissions season. This upcoming week, Emory / Goizueta, CMU / Tepper, Boston College / Carroll, Chicago / Booth, Yale SOM, Michigan / Ross, SMU / Cox and Georgia / Terry are scheduled to release their Round 1 decisions. Graham highlighted the upcoming Masters in Management (MiM) webinar series, scheduled for Tuesday and Wednesday of this week. Signups for these events are here, https://www.clearadmit.com/events The next livestream AMA is scheduled for Tuesday, December 16th; here's the link to Clear Admit's YouTube channel: https://bit.ly/cayoutubelive. Graham noted recently published articles on career placements in the Tech and Finance industries as well as a Fridays from the Frontline piece on the Eurout LGBTQ+ conference at London Business School. He then covered two admissions tips recently published by Clear Admit. The first focuses on the increasing importance of video essays in the MBA admissions process. The second admissions tip focuses on how best to do school research via communities of students, alumni and faculty. Graham highlighted three Real Humans pieces spotlighting students from IMD, IESE and Cambridge / Judge, and then we discussed the recently published Class of 2027 admissions profile from Harvard Business School. Finally, Graham profiled a recently published podcast that focuses on UNC / Kenan Flagler's Deans Fellows program. For this week, for the candidate profile review portion of the show, Alex selected two ApplyWire entries and one DecisionWire entry: This week's first MBA admissions candidate has a 695 GMAT score but is planning a retake. They only have two years of experience but are determined to begin their MBA program this season. This week's second MBA applicant has a whopping 755 GMAT score but only a 3.0 GPA. They are targeting next season for their MBA, as they only have 2.5 years of experience, to date. This week's final MBA candidate is choosing between the one-year MBA programs at Northwestern / Kellogg, CMU / Tepper and Emory / Goizueta. They want to do consulting post MBA, and their partner has an offer at Tepper. This episode was recorded in Paris, France and Cornwall, England. It was produced and engineered by the fabulous Dennis Crowley in Philadelphia, USA. Thanks to all of you who've been joining us and please remember to rate and review this show wherever you listen!

To help us unpack The South Africans stranded in Ukraine from a strategic and defence vantage point, Amy MacIver is joined by Helmoed Heitman — one of South Africa’s leading defence analysts, known for his expertise in battlefield dynamics, military law environments, and the complexities of foreign armed conflict. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

From being shot at in Syria to navigating the gang-controlled streets of Haiti, a new YouTube series is shining a light on some of Sky's most hard-hitting journalism. Hotspots takes you behind the scenes in hostile environments around the world to deliver the story behind the story. Our correspondents Stuart Ramsay and Alex Crawford join Niall Paterson to discuss their important work and where they'd like to go next. You can watch Hotspots here: youtube.com/@SkyNewsHotspots And subscribe so you don't miss an episode. Producers: Tom Gillespie & Emily Hulme Editor: Mike Bovill

ゲスト：坂口孝則さん（調達・購買コンサルタント） 2025年12月1日（月）「FrontLine Session」より 発信型ニュース・プロジェクト「荻上チキ・Session」 ★月～金曜日　17:00～20:00　TBSラジオで生放送 パーソナリティ：荻上チキ、南部広美 番組HP：⁠荻上チキ・Session⁠ 番組メールアドレス：⁠ss954@tbs.co.jp⁠ 番組Xアカウント：⁠@Session_1530⁠ ハッシュタグは ⁠#ss954 Learn more about your ad choices. Visit megaphone.fm/adchoices

Indigenous rangers from the Great Barrier Reef are learning coral spawning techniques in one of the largest reef restoration trials to date. The pilot program involves rangers working in the reefs off Queensland's Keppel Islands, which were hit hard by last year's mass coral bleaching event.

Every leg saved has a story behind it — and this week on The Heart of Innovation, you'll meet the nurse practitioners who live those stories every day. Kym McNicholas and Dr. John Phillips chat with four remarkable OhioHealth NPs — Chelsea Jones, Elizabeth Murray, Brittany Byce, and Rebecca Lawler — to share what it's really like to help patients fight peripheral artery disease (PAD) and critical limb ischemia inside a large hospital system. They open up about: The split-second decisions that can mean the difference between amputation and recovery The emotional moments that stay with them long after a shift ends The gaps in care they're constantly trying to close for PAD patients And yes… the hilarious "Nonsense Board" where they log the wild moments that keep them sane It's raw. It's real. It's the life of a limb-saving NP — equal parts heart, grit, urgency, and humor. If you or someone you love is living with PAD, struggling to navigate the system, or wondering what limb-saving care actually looks like behind the scenes, this episode will give you clarity, encouragement, and a whole new appreciation for the clinicians fighting for patients every single day. #TheHeartOfInnovation #PAD #LimbSavingCare #PeripheralArteryDisease #NursePractitioner #OhioHealth #VascularHealth #AmputationPrevention #LifeAndLimb #KymMcNicholas #DrJohnPhillips #PatientAdvocacy #ChronicDiseaseCare #FrontlineMedicine #HealthcareHeroes  

Seventeen years ago, India was shaken when Lashkar-e-Taiba terrorists launched 12 coordinated attacks across Mumbai, striking the Taj Mahal Palace Hotel, Chabad (Nariman) House, and other locations in the country's financial capital. The assault killed 166 people and injured over 300. Nine of the ten terrorists were killed, while the lone surviving attacker, Ajmal Kasab, was captured alive. In this episode of In Our Defence, host Dev Goswami and national security expert Sandeep Unnithan revisit the assault that became the Kargil of India's internal security. They take you deep inside the shadowy world of terrorist training, high-risk counter-terror operations and the elite response mechanisms that shaped India's modern security doctrine. From Special Forces–style training used by the attackers, to the MARCOS team's first response and the intense close-quarters battle inside the Taj Hotel and Chabard House. Unnithan revisits the tactics, planning and coordination failures that emerged during the 26/11 Mumbai Attack, offering rare insights into what changed and what still hasn't. The two discuss: - Terrorist training methods -Frontline decision-making -The evolution of India's counter-terror capabilities Tune in! Produced by Taniya Dutta Sound mixed by Aman Pal

Leaving the US after weeks on the road, we zoom out from New York and Washington and asks a question we almost never ask in Europe: what if the real future of geopolitics isn't in Brussels, Beijing or DC, but in Central Asia? To get there, we bring in historian Peter Frankopan, author of The Silk Roads, to map the region we lazily call “the Stans”; Kazakhstan, Uzbekistan, Tajikistan, Kyrgyzstan and Turkmenistan, plus Afghanistan, Iran and their neighbours. Together we unpack why this vast strip of land, once the beating heart of the Silk Roads, is suddenly back at the centre of the global game: home to huge reserves of oil, gas, uranium, rare earths and critical minerals, a young and growing population, and wedged between Russia, China, India, Pakistan and Iran. We hear how Central Asian states are learning to play everyone off against everyone and why the new Great Game isn't a neat East vs West story at all. If the world is getting more dangerous, more digital and more fragmented, what does it mean that Ireland is the EU's weak link on defence, with tiny cyber budgets, under-protected seabed cables and a very cosy version of neutrality? Hosted on Acast. See acast.com/privacy for more information.

ゲスト：能條桃子さん（「NO YOUTH NO JAPAN」代表理事、「FIFTYS PROJECT」代表） 2025年11月27日（木）「FrontLine Session」より ========================================= 発信型ニュース・プロジェクト「荻上チキ・Session」 ★月～金曜日　17:00～20:00　TBSラジオで生放送 パーソナリティ：荻上チキ、南部広美 番組HP：⁠⁠⁠⁠⁠荻上チキ・Session⁠⁠⁠⁠⁠ 番組メールアドレス：⁠⁠⁠⁠⁠ss954@tbs.co.jp⁠⁠⁠⁠⁠ 番組Xアカウント：⁠⁠⁠⁠⁠@Session_1530⁠⁠⁠⁠⁠ ハッシュタグは ⁠⁠⁠⁠⁠#ss954 Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of The FRONTLINE Dispatch, host Raney Aronson-Rath speaks with longtime FRONTLINE correspondent Evan Williams, director of The Rise of Germany's New Right. Together, they unpack how the hardline Alternative for Germany (AfD) party has surged in popularity, drawing young voters on TikTok, capitalizing on economic anxiety, and reframing nationalism for a new generation.

The full-scale Russian invasion of Ukraine is just a few months short of the four-year mark. PBS's Frontline, working with the Associated Press, will air "2000 Meters to Andriivka," a relentless portrait of life and death on the frontlines. Nick Schifrin spoke with filmmaker Mstyslav Chernov. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

"Training is useless if it's not enforced." Notable Moments [05:32] Anticipating problems is the foundation of training. [07:31] Enforcement matters just as much as teaching the standard. [08:58] Customer expectations reveal what training should cover. [13:31] Frontline experience exposes blind spots leaders miss. [15:29] Standards create consistency across every location. Great service comes from anticipation, clarity, and consistent training. Lee Cockerell shares practical lessons on how organizations can prepare for the problems they know are coming, learn from customers and employees, and build standards that ensure consistent service at every location. He explains why training must be enforced and how frontline workers reveal what excellence really looks like. Anticipating challenges is the key to creating a safe, reliable, and enjoyable customer experience. Read my blog for more from this episode.  Resources CockerellStore.com The Cockerell Academy About Lee Cockerell Mainstreet Leader Jody Maberry Travel Guidance Magical Vacation Planners are my preferred travel advisors. Reach out to have them help plan your next vacation. You can reach them at 407-442-2694.    

Reverification in Action with Frontline Lessons from the Field Randy Boner, Associate Director of Client Success, shares real-world lessons from the front lines of reverification—how automation, payer mapping, and orchestration reduce rework, improve accuracy, and keep coverage continuous through the busiest time of year. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Your staff might be showing up—but are they showing up with energy? In this episode, Fern dives into a powerful but often overlooked force in your pet resort: the energy your team brings into the building every day. It's not about how many hands you have on deck—it's about how those hands feel, act, and interact. From emotional labor to burnout red flags, this episode explores why the vibes behind the scenes might be the secret weapon (or hidden saboteur) of your business success.You'll get real insight into how to spot low-energy slumps, why timing tasks with staff energy peaks matters, and simple adjustments that can shift the whole tone of your business. Plus, Fern shares tips for creating a culture that fuels your team, boosts morale, and keeps clients coming back—without burning anyone out. If you're ready to stop managing people like schedules and start leading them like a true Overdog, this one's for you.

A new FRONTLINE documentary examines Ecuador's rapid descent from one of South America's most peaceful nations into a country gripped by violent conflict driven by the international drug trade.

The full-scale Russian invasion of Ukraine is just a few months short of the four-year mark. PBS's Frontline, working with the Associated Press, will air "2000 Meters to Andriivka," a relentless portrait of life and death on the frontlines. Nick Schifrin spoke with filmmaker Mstyslav Chernov. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

出演：永井玲衣さん（哲学者） 2025年11月25日（火）「FrontLine Session」より。 発信型ニュース・プロジェクト「荻上チキ・Session」 ★月～金曜日　17:00～20:00　TBSラジオで生放送 パーソナリティ：荻上チキ、西川あやの（代演） 番組HP：⁠⁠⁠⁠⁠⁠⁠荻上チキ・Session⁠⁠⁠⁠⁠⁠⁠ 番組メールアドレス：⁠⁠⁠⁠⁠⁠⁠ss954@tbs.co.jp⁠⁠⁠⁠⁠⁠⁠ 番組Xアカウント：⁠⁠⁠⁠⁠⁠⁠@Session_1530⁠⁠⁠⁠⁠⁠⁠ ハッシュタグは ⁠⁠⁠⁠⁠⁠⁠#ss954 Learn more about your ad choices. Visit megaphone.fm/adchoices

The full-scale Russian invasion of Ukraine is just a few months short of the four-year mark. PBS's Frontline, working with the Associated Press, will air "2000 Meters to Andriivka," a relentless portrait of life and death on the frontlines. Nick Schifrin spoke with filmmaker Mstyslav Chernov. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Tracing the dramatic and controversial rise of Robert F. Kennedy Jr., FRONTLINE examines how the scion of a storied dynasty endured tragedy and scandal, broke with the Democratic Party and his family, stoked conspiracy theories, and is reshaping government and public health.

Today:Ukrainian journalist and Oscar-winning documentary filmmaker Mstyslav Chernov presents his latest film “2000 Meters to Andriivka” tomorrow night on PBS. It offers a vantage point of war rarely seen in non-fiction films: a first-hand look at the toll of war on the frontline soldiers.

In this week's MBA Admissions podcast we began by discussing the current state of the MBA admissions season, a few interview invites continue to roll out. This upcoming week, IESE and London Business School are scheduled to release their Round 1 decisions. Graham highlighted the upcoming Masters in Management (MiM) webinar series, scheduled for December 2 and 3. Signups for these events are here, https://www.clearadmit.com/events The next livestream AMA is scheduled for this Tuesday, November 25; here's the link to Clear Admit's YouTube channel: https://bit.ly/cayoutubelive. Graham noted a recently published article on AI instruction in top MBA programs. This is clearly an important and evolving area. Graham also highlighted a Fridays from the Frontline article featuring two ex-military students at NYU / Stern, and an article focused on consulting placements at top MBA programs. He then covered two admissions tips recently published by Clear Admit. The first focuses on creating the MBA resume, and the second focuses on how to select recommendation writers for business school applications. Graham highlighted two Real Humans pieces spotlighting students from Northwestern / Kellogg and Vanderbilt / Owen, and then we discussed the recently published Class of 2027 profile from Columbia Business School. For this week, for the candidate profile review portion of the show, Alex selected three ApplyWire entries: This week's first MBA admissions candidate has a strong overall profile in the environmentally sustainable space. They have a 332 GRE and a 3.44 GPA. We discussed whether the GPA would be a liability. This week's second MBA applicant has a 740 GMAT but a 3.15 GPA. They applied to 15 programs in Round 1 and have received several interview invites. This week's final MBA candidate is from Portugal and has a strong GPA. They worry that their 645 GMAT might limit some of their opportunities. This episode was recorded in Madrid, Spain and Cornwall, England. It was produced and engineered by the fabulous Dennis Crowley in Philadelphia, USA. Thanks to all of you who've been joining us and please remember to rate and review this show wherever you listen!

Diana Mao joins Dr. Sandie Morgan as they explore how economic empowerment serves as a frontline defense against human trafficking, revealing why desperation—not just deception—drives vulnerable families into exploitation. https://youtu.be/NLM4TP2d_lQ   Diana Mao Diana Mao is a dynamic leader at the forefront of the fight against human trafficking and workforce development. As the President and Co-Founder of Nomi Network, she's helped raise and mobilize over 30 million dollars to create economic opportunities for survivors and women at risk. Her work has brought together corporate leaders, government agencies, and social impact partners to build pathways to freedom and stability. She's a Presidential Leadership Scholar and a New York Academy of Medicine Fellow, and her innovative approach has earned her awards like the NYU Alumni Changemaker Award and the Texas Women's Foundation Young Leader Award. She's advised Congress on key policy issues, and her voice is regularly heard on some of the world's biggest stages, including the United Nations, the Bush Presidential Center, and the Clinton Presidential Center. With degrees in Business Economics and Chinese from UC Santa Barbara and a Master's in Public Administration from NYU Wagner, Diana blends academic rigor with hands-on leadership. Key Points Economic vulnerability drives trafficking more than deception alone—when families face starvation and earn less than 75 cents a day, they may knowingly take dangerous jobs because desperation outweighs risk assessment. Nomi Network operates 42 training sites across India, Cambodia, and the United States, providing trauma-informed workforce training, job placement, and micro-enterprise support that creates sustainable alternatives to exploitative labor. Building capacity within existing community organizations—rather than disqualifying partners who don't meet predetermined standards—creates more sustainable and culturally contextualized anti-trafficking interventions. Living immersively in the communities being served allows organizations to co-design programs with survivors and understand the daily realities that shape vulnerability, from gathering water at 5 AM to facing harassment after 6 PM. Successful prevention requires creating bridges between vulnerable communities and the private sector, as demonstrated by Nomi Network's partnerships with major employers like India's largest manufacturers and Toyota subsidiaries that provide direct job pipelines. Youth in Dallas County's detention system who complete Nomi Network's apprenticeship programs secure jobs earning $18 per hour—more than double the minimum wage—fundamentally changing their economic trajectories and reducing trafficking vulnerability. The anti-trafficking movement is increasingly leveraging technology and AI as tools for prevention and intervention, recognizing that criminal networks are already using these technologies at exponential rates to target vulnerable populations. Self-care practices including morning exercise routines, faith-based reflection, and intentional rest enable sustained leadership in emotionally demanding anti-trafficking work, helping leaders operate from inspiration rather than obligation. Resources Nomi Network Invisible Children World Vision International Justice Mission (IJM) Hagar International Vanguard University Ending Human Trafficking Podcast Transcript [00:00:00] Diana Mao: And at the end of the survey he offered my male colleague, his youngest daughter, you like her, you take her. And as I looked into his eyes, I could see desperation and I didn't even know what, if he knew what he was doing. [00:00:11] Delaney: When your children sleep on bare ground and you earn 75 cents a day, risk management isn't just about losing your car. It's about facing the decision to take a job that might cost you everything or watching your family starve.

Cloud managed services are experiencing rapid growth, with the market projected to expand from approximately $50.62 billion in 2025 to $120 billion by 2035, reflecting a compound annual growth rate of 8.16%. This growth is driven by organizations across various sectors, including finance and healthcare, seeking to enhance their cloud operations and address cybersecurity risks. However, a widening performance gap among managed service providers (MSPs) is evident, as only the most capable firms are capitalizing on this demand. According to Service Leadership data, while the overall profitability of the MSP sector remains strong, not all providers are experiencing equal growth, raising concerns about competitive positioning.Recent surveys indicate that many businesses investing in artificial intelligence (AI) are not seeing financial returns, with only about 2% of Canadian business leaders reporting positive results from their generative AI investments. A study by KPMG highlights that many companies are still in the experimental phase of AI adoption, failing to integrate the technology effectively into their operations. Additionally, a significant skills gap exists among channel partners, with only 26% currently offering advanced network services with integrated AI capabilities. This disconnect between customer expectations and partner capabilities is contributing to the widening gap in performance.Frontline workers express concerns regarding the lack of transparency in AI integration within their workplaces. A survey conducted by Deputy found that while nearly half of workplaces utilize AI, only 25% of workers report regular interaction with it, and many are unaware of its usage. This communication gap can lead to mistrust and confusion among employees, which may hinder successful AI adoption. Despite these concerns, a majority of workers report satisfaction with AI's role in their tasks, indicating potential for positive outcomes if communication improves.For MSPs and IT service leaders, the current landscape presents both challenges and opportunities. The demand for cloud, AI, and managed services is surging, but success will depend on the ability to operationalize these technologies effectively. Providers must focus on enhancing their capabilities, improving communication with clients, and ensuring that they deliver measurable outcomes. As the market differentiates between high performers and those lagging behind, it is crucial for MSPs to adapt and evolve their services to meet the growing expectations of their clients. Three things to know today00:00 Cloud Demand Surges, CEO Priorities Shift, and MSP Performance Splits Into Clear Winners and Laggards05:40 Studies Show AI Investment Outpacing Capability, Leaving Firms Without ROI and Partners Struggling to Deliver10:00 AI Rollout Outpaces Employer Transparency, Creating Worker Confusion and Risk for IT Providers This is the Business of Tech.     Supported by:  https://mailprotector.com/mspradio/

Former NSA senior executive Mike Driscoll joins Cipher Brief's Brad Christian to dissect how America - and its allies - win or lose in the cognitive domain. From post-9/11 SIGINT dominance and its pitfalls to today's OSINT revolution powered by AI, Driscoll details why democracies keep ceding the narrative, what Oct. 7 revealed about messaging at speed, and how to rebalance "the exquisite" with the open. They break down gray zone tactics, attribution lags, tunnel warfare, and the policy/risk mindset shifts needed to shrink decision timelines from months to seconds. Driscoll argues that education, public-private integration, and mission-driven AI are now decisive. If you care about how the next conflict is fought - and who shapes the truth - this conversation is essential.

This week: Rancher and UK television host, Jay Doan from Blackleg Ranch, talks with Ian Welsh about how Blackleg Ranch has practiced regenerative agriculture mimicking historic bison movements to restore prairie grasslands. They discuss why resilience is the real language that resonates with ranchers, why neighbouring farms resist change even as their soil degrades. They highlight how generational transition, diversification, and a deep respect for the land shape the future of family agriculture in the US.   Plus: Innovation Forum's Anamya Anurag introduces the upcoming future of food and beverage forum, taking place in May 2026 in Minneapolis.   Host: Ian Welsh   Click here for information on how to get involved in the future of food and beverage forum USA.

ゲスト：安田浩一さん（ジャーナリスト） 2025年11月24日（月）「FrontLine Session」より 発信型ニュース・プロジェクト「荻上チキ・Session」 ★月～金曜日　17:00～20:00　TBSラジオで生放送 パーソナリティ：荻上チキ、南部広美 番組HP：⁠荻上チキ・Session⁠ 番組メールアドレス：⁠ss954@tbs.co.jp⁠ 番組Xアカウント：⁠@Session_1530⁠ ハッシュタグは ⁠#ss954 Learn more about your ad choices. Visit megaphone.fm/adchoices

“Before the pandemic, one in four San Francisco families struggled with food security; after, four out of ten Black and Latinx families are struggling.” - Kenneth Kim, Senior Director of Programs, GLIDEDrawn from our 105-episode COVID-19 series, this conversation revisits the early months of the global pandemic—and connects them to today's hunger crisis intensified by government shutdowns and SNAP cuts. Frontline leaders describe building pop-up pantries in days, serving thousands of outdoor meals, scaling home-delivered food for seniors, and standing up mobile hygiene and hotel-based shelters for unhoused neighbors.You'll hear from:SF-Marin Food Bank, Redwood Empire Food Bank & Meals on Wheels SFGlide Memorial Church & St. Anthony'sSimply the Basics, Lava Mae X & Hayes Valley BakeworksCommunity Forward SF, Tipping Point & Project Homeless ConnectKey themes:Demand outpacing supply across food and hygiene servicesSeniors, families, and communities of color on the front lines of hungerHow “radical hospitality” and one-stop hubs restore dignity and trust

From 'Play Tessie' (subscribe here): It's Gordo's turn to give his Who Says No proposal to Sammy and Pat which features a starting pitcher not mentioned as a trade candidate. Would the Red Sox be able to acquire Gavin Williams from the Guardians for Jarren Duran and Kutter Crawford? Also, Cleveland has no purpose to trade away Williams so they could be asking for more to make it more attainable. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

More than a decade ago, the Emmy-nominated documentary Poor Kids explored poverty in the United States as it's rarely seen: through the eyes of children. Born Poor tells the stories of the same children, now grown, chronicling their lives from childhood to the present day. The 90-minute documentary follows Kaylie, Johnny and Brittany across three chapters of their lives as they grow from kids to teenagers to adults, trying to pursue their dreams while dealing with an economy where they face more obstacles than opportunities — and trying to overcome the grinding poverty that shaped their childhoods.

They were high school students already getting up close and personal hands-on experience at the Jordan Academy for Technology and Careers (JATC) in their quest to become firefighters. On this episode of the Supercast, meet some recent Jordan School District graduates who spent this past summer on the front line fighting wildland fires in Utah. Hear how they got a jump start on their careers in high school, enrolled in the JATC Fire Science program. Find out what advice they have for current students eager to don their turnout gear and start their own careers as firefighters after graduation. Audio Transcription Transcription coming soon.

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Tackling the complex issue of perinatal mental health. Thinking Healthy (TH), a brief psychological intervention that can be delivered by trained and supervised community health care workers. It uses simple cognitive behavioral techniques to provide mothers with support and to improve mental health outcomes for the mother and new-born infant.In this fourth episode, Sarah Harrison, Director of the Red Cross Red Crescent Movement MHPSS Hub, speaks with Dr Waood Afara, Senior Mental Health and Psychosocial Support Officer at the International Rescue Committee (IRC) in Yemen‏, and Dr Elisabetta Dozio Mental Health and Psychosocial Support Specialist at Action Contre la Faim (Action Against Hunger- AAH) in France. Dr. Waood and Dr. Elisabetta are experts in both the research and practice of the Thinking Healthy intervention.Together we examine why dealing with maternal depression is important in humanitarian settings and explain how the intervention works in programming, including how to integrate TH in the workload of already overburdened community health workers. The link between caring for mothers and improving outcomes for children is explored, as are the cultural adaptations required to implement TH and measure its effectiveness. Key insights include importance of empathy and understanding from community and family members to support mothers in recovering, and the critical role that community health workers can play in improved maternal mental health if trained, supervised, and empowered. Key resources for practitionersThinking Healthy: A manual for psychological management of perinatal depression (WHO manual in multiple languages) Thinking Healthy Training Guide for community health workers and volunteers (MHPSS Hub) Baby Friendly Spaces: Holistic Approach in Emergencies (ACF Guide) Read more about the research:Dozio E, Wamba V, Pueugueu I. Adapting the Thinking Healthy Programme for Perinatal Depression: A Culturally Tailored Approach in Three Central African Countries. European Psychiatry. 2025;68(S1): S151-S151. doi:10.1192/j.eurpsy.2025.386Tomlinson, M., Chaudhery, D., Ahmadzai, H. et al. Identifying and treating maternal mental health difficulties in Afghanistan: A feasibility study. Int J Ment Health Syst 14, 75 (2020). Evidence from the Frontline: Mental Health in Crisis-Affected Contexts is a six-episode mini-series produced in collaboration between the MHPSS Hub and Elrha, designed for practitioners working in humanitarian and crisis contexts, the series highlights impactful interventions and practical insights from experts in the field. 

In this episode of The Frontline with FPM, Nathan Pierce interviews Mike Smith, co-founder and former president of HSLDA. Mike shares how he first discovered homeschooling in the early 1980s through Dr. Raymond Moore, leading his family to begin homeschooling and eventually drawing him into early legal battles to defend homeschool families in California. He explains how he met Mike Farris, how HSLDA was formed, and how their work—together with state partners like Family Protection Ministries—helped secure legal recognition for homeschooling nationwide. Mike also recounts the pivotal 2008 Jonathan L. case, when a court briefly ruled homeschooling illegal before reversing course and affirming its legality under California's private school exemption. HSLDA Website: https://hslda.org/ Become an HSLDA Member: https://hslda.org/join Donate to HSLDA: https://hslda.org/content/donate/ FPM Website: fpmca.org

Elon Musk's outspoken support for Germany's far-right Alternative for Deutschland (AfD) has intensified concerns among German officials and democracy advocates, and it features prominently in a new PBS FRONTLINE investigation into the rise of nationalist politics across Europe.

PBS's Frontline returns this week with a new in-depth documentary examining the evolving course of the war in Ukraine, offering viewers a granular look at a conflict now nearing its fourth year.

ゲスト：三輪記子さん（弁護士） 2025年11月17日（月）「FrontLine Session」より 発信型ニュース・プロジェクト「荻上チキ・Session」 ★月～金曜日　17:00～20:00　TBSラジオで生放送 パーソナリティ：プチ鹿島（荻上チキの代演）、南部広美 番組HP：⁠荻上チキ・Session⁠ 番組メールアドレス：⁠ss954@tbs.co.jp⁠ 番組Xアカウント：⁠@Session_1530⁠ ハッシュタグは ⁠#ss954 Learn more about your ad choices. Visit megaphone.fm/adchoices

The 30th COP climate summit is under way in the Brazilian city of Belém. BBC World Service Environment Correspondent Navin Singh Khadka has been covering COP since 2006. He joins us to share his insights on the inner workings of the summit and how it has changed over the years. In 2023, Algeria experienced devastating wildfires, particularly in the Kabylie region which is home to the Amazigh people. The Algerian government typically broadcasts brief updates in Algerian Arabic, which many people in affected regions do not speak. This lack of linguistic inclusivity means that vital information often fails to reach those who need it most. Khadija Maalej from BBC Media Action explains how a project called WISER has set about improving communications in order to save lives. For centuries, people fleeing slavery lived in isolation in Jalapão, in the east of Brazil. They survived by raising cattle and used controlled fires to renew the natural pasture for their herds. Then, in 2001, the government banned burning. The ban had the opposite effect to what was desired: Jalapão began to face gigantic wildfires until, in 2014, the state relented and began to encourage controlled burns again. João Fellet of BBC Brasil has travelled to Jalapão, to speak to the Quilombola people, and watch their controlled burns. This episode of The Documentary comes to you from The Fifth Floor, the show at the heart of global storytelling, with BBC journalists from all around the world. Presented by Faranak Amidi. Produced by Caroline Ferguson and Laura ThomasThis is an EcoAudio certified production. (Photo: Faranak Amidi. Credit: Tricia Yourkevich.)

In this moving conversation, we speak with Alisha, a therapist and Korean adoptee, about her lifelong search for identity and home. She shares the story of being adopted from Korea as an infant, growing up in a small Midwestern town, reuniting with her birth mother in her thirties, and navigating motherhood herself. We explore the myths of adoption, the grief that lives in the body, and what it means to come into community and consciousness as an adult adoptee.You can learn more about Alisha Bennett here. We also recommend this Frontline documentary, “South Korea's Adoption Reckoning.” LOVELINK is hosted by Brooklyn-based therapists Dr. Signe Simon and Dr. Simone Humphrey. If you'd like to contact us directly, send us an email to info@modernmind.co. 

Russia's war with Ukraine is about to enter yet another winter. Meanwhile in the US, Donald Trump is turning his attention to Russia's southern border in an effort to woo the nations of the South Caucasus with diplomacy. What are the US' goals and what does it hope to gain in pulling these nations closer while Russia is distracted in its fight against NATO to the West? Talking Geopolitics host Christian Smith is joined by GPF Chairman George Friedman to make sense of the latest developments. And for more analysis of the region, go to https://geopoliticalfutures.com/gpf-newsletter/ to get access to our free newsletter as well as our NEW special report: Reviving NATO's Eastern Line, by GPF Senior Analyst Antonia Colibasanu. This report is available for a limited time.

The Frontline documentary 'Born Poor' follows kids in three families who try to overcome poverty from childhood through their teen years to young adulthood.

In this episode of the EMS One-Stop podcast, host Rob Lawrence welcomes Dr. Hezedean Smith, who spotlights the human and operational toll of Hurricane Melissa on Jamaica and the wider Caribbean. Dr. Smith draws from first-hand perspective from the ground, detailing catastrophic damage to homes, utilities, roads and communications — which compounded the workload and emotional burden for Jamaica Fire Brigade (JFB) firefighters and EMS providers. Dr. Smith highlighted the Brigade's Amazon Wish List effort, which aims to route essential personal items and operational supplies directly to affected JFB members and stations to sustain continuity of operations and support responders' families. After the break, Dr. Smith switched hats as the newly elected President of NEMSMA to outline the association's renewed momentum: New association management support Expanded member services and credentials The inaugural NEMSMA Leadership Conference The NEMSMA Leadership Conference will take place in Washington, D.C., March 23-24, 2026, intentionally adjacent to EMS on the Hill to create a leadership-plus-advocacy “two-fer.” Highlights include keynote Gen. Robert Neller (Ret.), plus a deep bench of EMS leaders and educators. Memorable quotes from Dr. Hezedean Smith “Many homes destroyed, utility systems interrupted, critical infrastructure in terms of communities having the ability to communicate, leaving thousands displaced, even fire stations having operational challenges as it relates to communication and interoperability ... ” “I stayed in the local fire station. I wanted to be there with the men and women on the ground, to make sure that I had that communication, that constant contact with them.” “My focus will be on the firefighters and ensuring that we get enough supplies to go directly to the firefighters.” “We want to tear down silos. We want to redefine leadership and ensure that we continue to collaborate across this globe.” Additional resources: Jamaica Fire Brigade – Amazon Wish List National EMS Management Association (NEMSMA) NEMSMA Leadership Conference: Washington, D.C., March 23-24, 2026 EMS on the Hill, March 25-26, 2026, Arlington, Virginia International Journal of Paramedicine EMS One-Stop: General Robert Neller on ethical leadership and adaptability Episode timeline: 00:46 – Quick industry/policy update 01:27 – Set-up: Hurricane Melissa overview; impact stats and current situation 02:12 – Welcome Dr. Hezedean Smith 02:26 – Dr. Smith's backstory: Jamaica roots, USAF medic, Orlando FD, two fire chief roles, GES Consulting, Caribbean EMS focus 04:20 – First reactions to Melissa: scale of damage; compounded human toll 05:58 – Deployment cadence: aligning with JFB command, CDEMA, national EOC; travel hurdles; rapid integration on arrival 08:28 – Why existing relationships matter; staying in-station with crews; supporting leaders and frontline needs 11:13 – Call to action: Amazon wish list for responders' personal and operational needs; distribution via JFB logistics 13:20 – Specific needs (PPE, boots, clothing, hygiene, basic medical supplies) and the ongoing recovery realities 17:46 – NEMSMA — new president, renewed energy, new AMC, who NEMSMA serves 20:14 – Board/leadership shout-outs; programs (FTEP, ACPE), member services, momentum 22:49 – Conference preview (Mar 23–24, 2026, D.C.): theme — disruptive leadership; Gen. Robert Neller keynote; speaker lineup; proximity to EMS on the Hill 26:29 – IJOP collaboration and research-to-podcast pipeline; communications and sponsorship improvements 28:29 – Closing thanks; unified call to support JFB and engage with NEMSMA initiatives Rate and review the EMS One-Stop podcast Enjoying the show? Please take a moment to rate and review us on Apple Podcasts. Contact the EMS One-Stop team at editor@EMS1.com to share ideas, suggestions and feedback. Listen on Apple Podcasts, Amazon Music, Spotify and RSS feed.

Fr. Dom is back! James and Fr. Dom tackle one of the most misunderstood yet absolutely essential topics in the spiritual life: baptism. This is not just another Church formality. This is the dividing line between belonging to the Kingdom of God and the dominion of Satan.Drawing from Scripture, the Catechism, and the wisdom of the saints, TMC lays out with clarity and conviction what baptism truly does: freeing us from original sin, making us sons of God, and incorporating us into the Body of Christ. Without it, you remain enslaved to sin and outside the family of God.You'll hear why the early Church Fathers, councils, and even the Protestant revolution itself reveal that there's no salvation without baptism. Fr. Dominic doesn't sugarcoat the truth — he calls modern men to wake up to the spiritual reality of this sacrament and to recognize the Church as the one true means of salvation given to us by Christ Himself.James and Fr. Dom also confront why our age resists authority, why relativism and pride have blinded so many, and why men must reclaim their God-given duty to lead their families into the faith by baptizing their children without hesitation.In this episode, you'll discover:The biblical foundation of baptism — from Acts to Corinthians to the Great Commission.Why baptism isn't symbolic but supernatural warfare.How baptism undoes the curse of Adam and Eve and reclaims your soul for God.Why relativism, pride, and modernism are destroying moral order — and what Catholic men must do to restore it.The spiritual danger of delaying baptism for your children.Why contemplating death (memento mori) prepares your soul for heaven.Challenge to Men: If you have children who aren't baptized — schedule it now. Don't delay. Fathers, you are the protectors of your family's souls. Take your post. Lead your household back under the protection of God. Baptism is the first weapon in your family's arsenal against hell.3 Powerful Quotes:“Through baptism, we are freed from sin and reborn as sons of God. We become members of Christ and sharers in His mission.”“If you're not going to follow God, then who do you belong to? Baptism begins to undo definitively the faults of our first parents in the garden.”“Parents, you're supposed to protect your child. Why would you let them walk this world owned by Satan when baptism can claim them for God?”Key Takeaway: Baptism isn't optional — it's the decisive act that transfers your soul from the dominion of darkness to the Kingdom of Christ. Every Catholic man must treat it as a matter of eternal life and death.Send us a text Support the showPlease prayerfully consider supporting the podcast on our Buy Me A Coffee page. to help grow the show to reach as many men as possible! Thank you for your prayers and support. Be sure to follow us on X for more great content. As always, please pray for us! We are men who strive daily to be holy, to become saints and we cannot do that without the help of the Holy Ghost! Subscribe to our YouTube page to see our manly and holy faces Check out our website Contact us at themanlycatholic@gmail.com

AP correspondent Charles de Ledesma reports on the latest Russia attacks in Ukraine.

Day 1,357.Today, the battle for Pokrovsk continues to rage on with 300 Russian soldiers now in the city, pressing forward to the north. We discuss the corruption probe in Ukraine targeting one of Zelensky's close allies and how it led to the president's debacle over the summer when he tried to curtail Ukraine's two anti-corruption agencies. Finally, we zoom in on Lavrov's disappearance from the public eye in the last couple of weeks and on the patterns of drone incursions across Europe these past two months. ContributorsAdélie Pojzman-Pontay (Journalist and Producer). @adeliepjz on X.Memphis Barker (Senior Foreign Correspondent). @memphisbarker on X.Roland Oliphant (Chief Foreign Analyst). @RolandOliphant on X.Joe Barnes (Brussels Correspondent). @Barnes_Joe on X.SIGN UP TO THE ‘UKRAINE: THE LATEST' WEEKLY NEWSLETTER:http://telegraph.co.uk/ukrainenewsletter Each week, Dom Nicholls and Francis Dearnley answer your questions, provide recommended reading, and give exclusive analysis and behind-the-scenes insights – plus maps of the frontlines and diagrams of weapons to complement our daily reporting. It's free for everyone, including non-subscribers.CONTENT REFERENCED:‘We are losing Pokrovsk': Russia nears biggest gain since 2023, The Telegraphhttps://www.telegraph.co.uk/world-news/2025/11/11/pokrovsk-ukraine-russia-gain-volodymyr-zelensky-gen-syrskyi/Who is Timur Mindich, Zelensky's secretive associate at the center of a major corruption probe?, Kyiv Independenthttps://kyivindependent.com/who-is-timur-mindich/?mc_cid=721276d3ca&mc_eid=4a5b852913Where's Sergei Lavrov? Rumours swirl over the fate of Putin's foreign affairs enforcer, The Telegraphhttps://www.telegraph.co.uk/politics/2025/11/10/the-rumours-swirling-over-the-fate-of-sergei-lavrov/Mapped: Russia's new drone war against Europe, The Telegraphhttps://www.telegraph.co.uk/world-news/2025/11/11/mapped-russia-new-drone-war-against-europe/Poppies and cornflowers became symbols of November 11 thanks to women forgotten by history, Le Mondehttps://www.lemonde.fr/en/m-le-mag/article/2025/11/11/poppies-and-cornflowers-became-symbols-of-november-11-thanks-to-women-forgotten-by-history_6747339_117.htmlThe Poppy Lady, The Story of Madame Anna Guérin and the Remembrance Poppyhttps://www.pen-and-sword.co.uk/The-Poppy-Lady-Hardback/p/21829Subscribe: telegraph.co.uk/ukrainethelatestEmail: ukrainepod@telegraph.co.uk Hosted on Acast. See acast.com/privacy for more information.

Episode Summary: Marine veteran Andrew Bain spent the past 20 years living and working in Ukraine. He and Adm. Ihor Voronchenko (Ret), former commander of the Ukrainian Navy, join hosts Heather "Lucky" Penney and Lt. Gen. David Deptula, USAF (Ret.) for an inside look at technical and tactical innovation in the fight for survival against Russian aggression. Credits: Host: Heather "Lucky" Penney, Director of Research, The Mitchell Institute for Aerospace Studies Producer: Shane Thin  Executive Producer: Douglas Birkey Guest: Lt Gen David A. Deptula, USAF (Ret.), Dean, The Mitchell Institute for Aerospace Studies Guest: Adm. Ihor Voronchenko, Ukrainian Navy (Ret.) Guest: Andrew K. Bain, Executive Director and Member, Board of Directors, Ukrainian Freedom Fund Language Interpreter: Olha Paniuk Links: Subscribe to our Youtube Channel: https://bit.ly/3GbA5Of Website: https://mitchellaerospacepower.org/ Twitter: https://twitter.com/MitchellStudies Facebook: https://www.facebook.com/Mitchell.Institute.Aerospace LinkedIn: https://bit.ly/3nzBisb Instagram: https://www.instagram.com/mitchellstudies/ #MitchellStudies #AerospaceAdvantage #Ukraine #Europe #Russia

Day 1,351.Today, as reports from Pokrovsk indicate Russian troops now hold positions across nearly the entire city, prosecutors in Kharkiv launch a new war crimes investigation after footage emerged of an alleged Russian FPV drone strike on two civilians carrying a white flag near Kharkiv. We also examine today's Joint Expeditionary Force meeting in Norway – asking whether it's wise for the group to brand itself as “NATO's first responders” – before doing a deep dive into recent cases of Ukrainian and Russian spycraft. Later, we speak with the commander of a Ukrainian drone unit who helped destroy Russian forces following the so-called “breakthrough” in Dobropillya.ContributorsDominic Nicholls (Associate Editor of Defence). @DomNicholls on X.Francis Dearnley (Executive Editor for Audio). @FrancisDearnley on X.With thanks to Dimko Zhluktenko.SIGN UP TO THE ‘UKRAINE: THE LATEST' WEEKLY NEWSLETTER:http://telegraph.co.uk/ukrainenewsletter Each week, Dom Nicholls and Francis Dearnley answer your questions, provide recommended reading, and give exclusive analysis and behind-the-scenes insights – plus maps of the frontlines and diagrams of weapons to complement our daily reporting. It's free for everyone, including non-subscribers.CONTENT REFERENCED:Learn more about Dimko's charity, Dzyga's Paw:https://dzygaspaw.com/ Dom's story on MI5 chief's warnings (The Telegraph):https://www.telegraph.co.uk/news/2025/10/16/sir-ken-mccallum-mi5-china-spy-scandal-national-security/ The Ukrainian double-agent playing Russia at its own game (The Telegraph):https://www.telegraph.co.uk/world-news/2025/11/01/ukraine-russia-war-double-agent-security-services/ A champion like no other: The curious life of a Unit 29155 operative (The Insider):https://theins.ru/en/inv/286477 Russia moves to year-round conscription from 2026 (Kyiv Independent):https://kyivindependent.com/putin-signs-law-allowing-year-round-conscription-in-russia/?mc_cid=fb29c7d440&mc_eid=08d0680a95 Is there a risk of encirclement in Pokrovsk and what awaits Myrnohrad? Soldiers explain (Hromadske):https://hromadske.ua/en/war/254005-ti-khto-v-pokrovsku-na-peredovykh-pozytsiiakh-vze-v-pryntsypi-v-otochenni-z-iakoho-malo-shansiv-vyyty Subscribe: telegraph.co.uk/ukrainethelatestEmail: ukrainepod@telegraph.co.uk Hosted on Acast. See acast.com/privacy for more information.